Connect with Us at the Upcoming Events

With in-person events back again, Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at 2022 BIO International Convention in June (booth #1754) and at the 13th Annual World ADC San Diego in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!

Book a Meeting

FcgRIIa-H ADCP Reporter Assay Kit, Core (CAT#: CB-P220-K) Datasheet

Product Type
Antibody-dependent cell-mediated phagocytosis (ADCP) is an important mechanism of action (MOA) of therapeutic antibodies, which aims to recognize and mediate the elimination of virus-infected or diseased (such as tumor) cells. And antibody-dependent cell-mediated The different cytotoxicity (ADCC) is mainly mediated by FcγRIIIa expressed on NK cells. ADCP can be mediated by FcγRIIa (CD32a), FcγRI (CD64) and FcγRIIIa (CD16a) by monocytes, macrophages, neutrophils and Dendritic cell-mediated. The levels of various receptors are highly dynamic and are affected by cell lineage, tissue microenvironment and local inflammation. These three receptors can participate in antibody recognition, immune receptor clustering and signaling Transduction events lead to ADCP; however, blocking studies have shown that FcγRIIa is the main FcγR receptor involved in this process.

Current methods for measuring ADCP rely on the isolation of human primary monocytes, the differentiation into macrophages in vitro, and the measurement of target cell phagocytosis. Because they rely on donor primary cells, complex assay protocols and substandard assay reagents, these assays are laborious and highly variable. As a result, it is difficult to establish these assays in a quality-controlled drug development environment.

The FcγRIIa-HADCP Reporter core kit is a bioluminescent cell-based assay, which overcomes the limitations of existing assays and can be used to measure antibodies and other antibodies with Fc domains (including specific binding and activation of FcγRIIa) The effectiveness and stability of biological agents.
1×96 wells

Figure 1 The FcγRIIa-H ADCP Reporter Bioassay reflects the MOA and specificity of antibodies designed to bind and activate FcγRIIa-H. Panels A and B. Increasing concentrations of trastuzumab (anti-HER2) or rituximab (anti-CD20) were incubated with either SKBR3 (HER2+) or Raji (CD20+) target cells and FcγRIIa-H Eff ector Cells, as indicated.

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *